41O Stock Chart & Stats
€1.48
€0.41(38.32%)
At close: 4:00 PM EDT
€1.48
€0.41(38.32%)
Day’s Range― - ―
52-Week Range€0.15 - €2.80
Previous CloseN/A
Volume600.00
Average Volume (3M)4.61K
Market Cap
€158.35M
Enterprise Value€36.28
Total Cash (Recent Filing)€7.75M
Total Debt (Recent Filing)€27.19M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 13, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding186,997,000
10 Day Avg. Volume5,019
30 Day Avg. Volume4,611
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.52Price Target Upside205.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)€11.86M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval For LYTENAVAFDA approval is a durable structural milestone enabling U.S. commercialization of LYTENAVA. Approval removes a major regulatory obstacle, permits product launch activities and payer engagement, and converts the company from purely development-stage to a potential revenue-generating commercial entity over the coming months.
First-in-class Ophthalmic Bevacizumab With ExclusivityBeing first FDA-approved ophthalmic bevacizumab with a long exclusivity window provides a sustainable competitive edge. This status can shift prescribing from off-label compounding to an approved product, supporting durable market share gains and pricing/payer negotiating leverage in the large U.S. retina market.
Established Capital-raising Channels And Shareholder ApprovalsThe company has demonstrated ongoing access to equity markets via a shelf, registered direct placements and ATM capabilities, and shareholder approval to expand authorized shares. This financing flexibility is a durable enabler to fund a launch, build a retina sales force and support reimbursement programs while commercialization ramps.
Bears Say
Negative Shareholder Equity / Pressured Capital StructureLong-standing negative equity indicates accumulated losses have eroded the capital base, weakening balance-sheet resilience. This structural weakness reduces borrowing capacity, heightens refinancing and covenant risk, and increases the likelihood of future dilutive financings if commercial cash flows are insufficient.
Persistent Operating Cash BurnConsistent negative OCF and FCF show the business historically consumes cash to fund operations. Even with a product launch, the need for durable cash generation is urgent; absent rapid positive cash conversion, the company will remain dependent on external funding, constraining long-term strategic options.
Deep Losses And Negative Gross Profit Despite Revenue Step-changeA revenue increase paired with negative gross profit highlights structural margin or accounting issues that undermine unit economics. Until gross margin sustainability is demonstrable, the company faces a long path to profitability; persistent deep operating losses will pressure cash and require cost or pricing changes to rectify.
Outlook Therapeutics News
41O FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was €0.15 and its highest was €2.80 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is €158.35M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -€0.139 earnings per share for the quarter, missing the consensus estimate of -€0.105 by -€0.034.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 186,997,000 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -€0.139 in its last earnings report, missing expectations of -€0.105. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in DE:41O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.52 (205.18% Upside)
€4.52 (205.18% Upside)
Blogger Sentiment
Bullish
DE:41O Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €4.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
41O Stock 12 Month Forecast
Average Price Target
€4.52
▲(205.18% Upside)